Janssen Search
Search results
Four Principles to Cultivate Diversity and Inclusion
Four Principles to Cultivate Diversity and Inclusion “Strength lies in difference, not in similarities,” wrote Steven Covey, author of The 7 Habits of Highly Effective People. Johnson & Johnson has embraced this principle ever since its inception in ...
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023
Sep 05, 2023 United States Key analyses examine long-term safety and efficacy of medicines for treatment-resistant depression and schizophrenia Titusville, New Jersey, September 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson ...
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
May 16, 2024 Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential ...
How Surprising New Research Is Tapping the Powers of the Immune System
Article Block Text: Article Type: Research and Innovation Immunology How Surprising New Research Is Tapping the Powers of the Immune System Your immune system does so much more than simply fight off colds. In recognition of National Autoimmune Disease ...
The Power of Precision Medicine for Patients
The Power of Precision: How J&J is Working to Deliver the Promise of Precision Medicine to Patients with Complex Disease DNA Day on April 25 is an annual, global celebration of the discovery of the double helix structure of deoxyribonucleic acid ...
Opening Vaccines Launch Facility speakers
Oct 24, 2018 Speakers Inspiring and engaging presentations and panal discussions will hightlight why it is important to "invest locally, to protect globally". View the complete program of the symposium. Moderator Guest speakers/panelists ...
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
Jan 08, 2024 United States Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to ...
Dual Perspectives on Digital Twins in Interception Science
Dual Perspectives on Digital Twins in Interception Science In the 1800s, there were several ways to photograph a single image. As image capture was refined, people noticed that successive still photos – or data points – stacked one after another at 10 ...
Commitment to Immunodermatology Newsroom
Welcome to the Johnson & Johnson Immunodermatology Newsroom! Below, please find the latest data, content, meeting news and leadership messages about our progress and commitment to developing transformational approaches and innovative medicines for ...
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
Apr 08, 2024 United States New exploratory analysis demonstrates consistent results of XARELTO ® in treating elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention XARELTO ® is one of the most ...